Oppenheimer Maintains Veru Inc(VERU.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsNov 5 16:31 ET · Ratings

Veru Announces Meta-analysis Of Body Composition Data From Older Patients With Obesity Which Supports Potential For Enobosarm To Optimize Weight Loss At ObesityWeek

BenzingaNov 5 08:38 ET

Express News | Veru Inc - Topline Results From Phase 2B Quality Trial Expected in January 2025

ReutersNov 5 08:32 ET

Express News | Veru Inc - Enobosarm Generally Well-Tolerated With No Increase in Gastrointestinal Side Effects

ReutersNov 5 08:31 ET

Express News | Veru To Present Meta-Analysis of 4 Previous Randomized Clinical Trials That Support Potential Of Enobosarm To Optimize Weight Loss At ObestiyWeek

BenzingaOct 21 08:41 ET

"Weight-loss miracle drug" causing muscle loss, biotechnology companies like Regeneron Pharmaceuticals (REGN.US) are developing new treatments.

Wegovy and Zepbound, along with other GLP-1 class drugs, have significant effects on weight loss, but this weight loss largely reduces muscle mass.

Zhitong FinanceOct 14 02:42 ET